NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models

SIMPLE SUMMARY: Epidermal growth factor receptor (EGFR) inhibitors are approved by the Food and Drug Administration (FDA) for the treatment of several cancers including head and neck squamous cell carcinoma (HNSCC). It has been reported that activating mutations in PIK3CA, which are relatively commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hua, Peyser, Noah D., Zeng, Yan, Ha, Patrick K., Johnson, Daniel E., Grandis, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833811/
https://www.ncbi.nlm.nih.gov/pubmed/35158773
http://dx.doi.org/10.3390/cancers14030506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833811/
https://www.ncbi.nlm.nih.gov/pubmed/35158773
http://dx.doi.org/10.3390/cancers14030506

Ejemplares similares